Gary Owens, MD, president of Gary Owens Associates, addresses how payers can improve outcomes for persons who have pulmonary arterial hypertension (PAH).
Gary Owens, MD, president of Gary Owens Associates, talks next steps payers can take to improve outcomes among persons living with pulmonary arterial hypertension (PAH), including stepping up education effort and improving medication access.
Transcript
What can payers do to make progress against PAH?
This is a disease that is often misunderstood, underrecognized, and underdiagnosed. Hence, that 2- to 3-year journey from symptom onset. So I think payers can hopefully play a role here, too, by helping educate the community. Now, the problem is, trying to get this message across to primary care physicians who are very, very busy with many other things, including the COVID-19 pandemic.
It’s easily possible for a disease that affects 5 to 10 per 1 million to get lost in the shuffle. But I think what it really does say, when these patients are identified by payers, getting case managers involved, and getting those case managers to coordinate that team approach I talked about, as well as making sure that patients have access to the proper pharmaceutical care, is what payers could and should be doing. Not only now but going forward.
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Perioperative Nivolumab Boosts NSCLC Survival: CheckMate 77T Trial
May 16th 2024This interim analysis of the CheckMate 77T trial, outcomes were compared between adult patients receiving neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo for resectable non–small cell lung cancer (NSCLC).
Read More